Lunsumio
Payments companies reported to CMS as associated with Lunsumio. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lunsumio, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lunsumio
These are the largest totals companies reported as associated with Lunsumio. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Vincent Herrin | Jackson, MS | Hematology (Internal Medicine) | $63,512.09 |
| Daniel Kerr II | Tampa, FL | Hematology & Oncology | $38,535.51 |
| Amy Sidorski | Aurora, CO | Nurse Practitioner | $37,295.55 |
| Sujith Kalmadi | Chandler, AZ | Hematology & Oncology | $33,230.90 |
| Tara Graff | Clive, IA | Medical Oncology | $28,134.25 |
| Matthew Lunning | Omaha, NE | Medical Oncology | $27,911.42 |
| Haifaa Abdulhaq | Fresno, CA | Hematology & Oncology | $26,330.32 |
| Adolfo Diaz | San Antonio, TX | Hematology & Oncology | $25,820.99 |
| Mark Fesler | Saint Louis, MO | Hematology & Oncology | $22,603.70 |
| Khuda Khan | Louisville, KY | Hematology & Oncology | $22,329.85 |
Prescribed Lunsumio?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.